— Improves Phexxi coverage for more than 5.8
million New York lives —
— Year-to-date, Evofem has gained Phexxi
coverage for more than 22.1 million new lives
—
SAN
DIEGO, April 12, 2023 /PRNewswire/
-- Evofem Biosciences, Inc., (OTCQB: EVFM) today
announced a major new win in New York
state that improves coverage for Phexxi® (lactic acid,
citric acid and potassium bitartrate), its hormone-free
contraceptive vaginal gel, for more than 5.8 million lives
statewide.
New York Medicaid transitioned to a single Preferred Drug List
effective April 1, 2023, that
includes no Prior Authorization requirement on Phexxi. This
facilitates access to Phexxi for women covered by New York
Medicaid, the largest of all Commercial and Medicaid payers in
New York.
In the first quarter of 2023, Evofem gained Phexxi coverage for
16.3 million new lives from payers including Mississippi Medicaid,
Indiana State Medicaid, multiple Blue Cross Blue Shield plans,
and the largest commercial payer in Michigan.
About Evofem Biosciences, Inc.
Evofem
Biosciences, Inc., is developing and commercializing
innovative products to address unmet needs in women's sexual and
reproductive health. The Company's first FDA-approved
product, Phexxi® (lactic acid, citric acid
and potassium bitartrate), is a hormone-free,
on-demand prescription contraceptive vaginal gel. It comes in a box
of 12 pre-filled applicators and is applied 0-60 minutes before
each act of sex. Learn more
at phexxi.com and evofem.com.
Phexxi® is a registered trademark of Evofem Biosciences,
Inc.
Investor Contact
Amy Raskopf
Evofem Biosciences,
Inc.
araskopf@evofem.com
(917) 673-5775
View original content to download
multimedia:https://www.prnewswire.com/news-releases/evofem-wins-phexxi-coverage-with-largest-payer-in-new-york-with-no-prior-authorization-required-301795517.html
SOURCE Evofem Biosciences, Inc.
